QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Creating Personalized Immunotherapy to Target the Most Common Cancer Affecting Women

Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is working to develop a novel, personalized immunotherapy treatment for patients with advanced breast cancer. A recent article further discussing BriaCell reads, “Improving the efficacy, safety and cost of care for those who are annually diagnosed with breast cancer continues to be at the forefront of medical research. An estimated 266,120 new cases of breast cancer are projected to be diagnosed in U.S. women during 2018, according to the National Cancer Institute (NCI)  (http://ibn.fm/cUSKe). Female breast cancer represents 15.3 percent of all new cancer cases in the U.S., with nearly 41,000 women expected to die of the disease in 2018, according to the NCI. Breast cancer is identified as the most commonly occurring cancer in women around the globe and the second most common cancer overall, according to the World Cancer Research Fund International (http://ibn.fm/sVNYK).”

To view the full article, visit http://ibn.fm/hTvuh

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php